

Amendments to Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-18 (Cancelled)

19. (Currently Amended) A method of enhancing inhibition of nicotine metabolism by a CYP2A6 inhibitor in an individual comprising administering to the individual an effective amount of a substance which selectively inhibits CYP2A6, and an effective amount of an inhibitor of CYP2B6CYP2A6, wherein the substance is at least one member selected from the group consisting of coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl, (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, micenazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen.

20. (Cancelled Herein)

Claims 21-22 (Previously Cancelled)

23. (Currently Amended) A pharmaceutical composition for regulating the metabolism of nicotine to cotinine comprising an effective amount of a substance which selectively inhibits CYP2A6 and an effective amount of an inhibitor of CYP2B6CYP2A6, wherein the substance comprises at least one member selected from the group consisting of coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone,

isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl, (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N -nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, ~~miconazole~~, ~~clotrimazole~~, ~~pilocarpine~~, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen, and mixtures thereof.

24. (Cancelled Herein)

Claims 25-26 (Previously Cancelled)

27. (Currently Amended) A method for treating a condition requiring regulation of nicotine metabolism to cotinine in an individual comprising administering to the individual an effective amount of a substance which selectively inhibits CYP2A6, and an effective amount of an inhibitor of CYP2B6CYP2A6, wherein the substance is at least one member selected from the group consisting of coumarin, furacoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl, (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N -nitrosodialkylamine, nitropyrene, menadione, imidazole[[,]] antimycotics, ~~miconazole~~, ~~clotrimazole~~, ~~pilocarpine~~, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen, and mixtures thereof; and wherein the condition requiring regulation of nicotine metabolism is dependent tobacco use.

28. (Cancelled Herein)

Claims 29-38 (Previously Cancelled)

39. (Previously Presented) The method of claim 19, wherein the substance is methoxsalen or a derivative thereof.

40. (Previously Presented) The method of claim 27, wherein the substance is methoxsalen or a derivative thereof.

41. (Previously Presented) The method of claim 23, wherein the substance is methoxsalen or a derivative thereof.

Claims 42-46 (Previously Cancelled)

47. (New) The method of claim 19, wherein the imidazole antimycotic is miconazole, clotrimazole or pilocarpine.

48. (New) The method of claim 23, wherein the imidazole antimycotic is miconazole, clotrimazole or pilocarpine.

49. (New) The method of claim 27, wherein the imidazole antimycotic is miconazole, clotrimazole or pilocarpine.